Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

McKesson (MCK) concluded the recent trading session at $585.08, signifying a +0.57% move from its prior day's close.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on McKesson (MCK – Research Report), with a price target of ...

Park Avenue Securities LLC lessened its position in McKesson Co. (NYSE:MCK – Free Report) by 2.5% during the fourth quarter, according to the company in its most recent filing with the Securities & ...

AdvisorNet Financial Inc lessened its holdings in McKesson Co. (NYSE:MCK – Free Report) by 11.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional ...

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

especially in specialty products and GLP-1 medications, as well as contributions from Prescription Technology Solutions and Medical-Surgical Solutions. Furthermore, McKesson raised its fiscal 2025 ...

With a market cap of $74.3 billion, Irving, Texas-based McKesson Corporation (MCK) is a global healthcare services and ...

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the ...

Cardinal Health’s profit margin lags behind peers, impacting growth. See why CAH stock’s outlook may be hindered by legal ...